AxoGen, Inc. to Feature Nerve Repair Solutions at the American College of Oral and Maxillofacial Surgeons (ACOMS) Annual Scientific Conference and Exhibition

Share Article

Use of Avance® Nerve Graft in Repair of Oral Nerve Injuries, Provides Opportunity for Restoration of Nerve Function Resulting in Positive Clinical Outcomes

AxoGen Logo

AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced its participation in the 2016 American College of Oral and Maxillofacial Surgeons (ACOMS) Annual Scientific Conference and Exhibition taking place in San Juan, Puerto Rico from April 9-12, 2016.

“The oral maxillofacial (OMF) nerve repair market is an exciting opportunity with an unmet clinical need that we are addressing with our current portfolio of nerve repair products,” commented Karen Zaderej, President and Chief Executive Officer. “AxoGen’s nerve repair portfolio, provides surgeons with clinical options to repair oral nerve injuries resulting in the restoration of nerve function and improve sensory scores.”

An interactive panel, hosted by Dr. John Zuniga, DMD, MS, PhD and Dr. Michael Miloro, DMD, MD, FACS, will discuss current clinical data, evidence based repair algorithms, repair optimization case planning, time saving approaches, and clinical cases.

In 2015, Dr. Zuniga, published “Sensory Outcomes After Reconstruction of Lingual and Inferior Alveolar Nerve Discontinuities Using Processed Nerve Allograft – a Case Series” in the Journal of Oral and Maxillofacial Surgery. This study followed 21 subjects with 23 severed nerve injuries in which Avance® Nerve Grafts, in lengths of up to 70 mm, were used to make the repair. Dr. Zuniga’s findings concluded that 87% of subjects experienced improved neurosensory scores.

Dr. Miloro’s research “Lingual Nerve Repair: To Graft or Not to Graft?” was also published in 2015 in the Journal of Oral and Maxillofacial Surgery. This study followed 47 lingual nerve injuries repaired by either direct coaptation or nerve grafting. Dr. Miloro’s findings concluded that 89% of the nerve grafting repairs reported improved neurosensory scores.
Each of these independent studies have demonstrated the utility of AxoGen’s nerve repair portfolio in the management of these devastating nerve injuries, with patients reporting return of critical nerve function.

Dr. Zuniga is Professor and Chairman, Division of Oral and Maxillofacial Surgery, Departments of Surgery, Neurology & Neurotherapeutics, University of Texas Southwestern Medical Center and Robert V. Walker, DDS, Chair in Oral and Maxillofacial Surgery, University of Texas Southwestern Medical Center. Dr. Miloro is Professor and Department Head, Department of Oral and Maxillofacial Surgery, University of Illinois at Chicago College of Dentistry, Program Director, Advanced Education Program in Oral and Maxillofacial Surgery, University of Illinois at Chicago College of Dentistry and Division Chief, Oral Surgery, University of Illinois Medical Center.

About AxoGen, Inc.

AxoGen (AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Along with these core surgical products, AxoGen also offers AxoTouchTM Two-Point Discriminator and AcroValTM Neurosensory & Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation, assessing return of sensory, grip and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2016 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer

EVC Group
Michael Polyviou/Doug Sherk – Investor Relations            
mpolyviou(at)evcgroup(dot)com; dsherk(at)evcgroup(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Polyviou/Doug Sherk - Investor Relations
EVC Group
+1 212.850.6020
Email >
Visit website